论文部分内容阅读
目的 :分析他巴唑致粒细胞缺乏症 (粒缺 )的临床特点 ,探讨有效治疗方法。方法 :回顾性分析 2 9例他巴唑致粒缺的临床资料。结果 :2 3例粒缺发生于服他巴唑后 4～ 1 2周 ,口服升白细胞药物组白细胞开始上升时间为 ( 6.2 6± 1 .48) d,上升至正常的时间为 ( 1 4.0 4± 2 .36) d,而联合用重组人粒细胞集落刺激因子 ( rh G- CSF)或重组人粒 /巨噬细胞集落刺激因子 ( rh GM- CSF)组分别为 ( 2 .5 0± 1 .1 7) d和 ( 5 .2 5± 1 .42 ) d。结论 :他巴唑致粒缺的危险阶段是治疗初 1～ 3月 ,rh G- CSF或 rh GM- CSF是治疗此类粒缺的一种有效的方法
Objective: To analyze the clinical features of methimazole-induced agranulocytosis and discuss the effective treatment. Methods: A retrospective analysis of 29 cases of methimazole caused by the lack of clinical data. Results: Twenty-three cases of granulomarexposure occurred 4 to 12 weeks after the dose of metadalaprol, and the leukocyte start rising time was (6.26 ± 1.48) d in the oral leukotriene drug group and increased to normal time (1 4.04 ± 2.36) d, respectively, while the combination of recombinant human granulocyte colony stimulating factor (rh G-CSF) or recombinant human granulocyte / macrophage colony stimulating factor (rh GM-CSF) .1 7) d and (5 .2 ± 1 .42) d. CONCLUSIONS: The dangerous phase of methimazole-induced neutropenia is the first to third months of treatment. Rh G-CSF or rh GM-CSF is an effective method for the treatment of such nephridial